| Priv. Log Entry No. | IDR No. Responsive To | Bates Range | Document Date | Document Type | Description | Author(s) | Recipient(s) | CC / Other Recipients | Privilege Asserted | Privilege Basis Description |
| PL-001 | 1 | PRIV-000001 – PRIV-000004 | 2022-06-02 | Engagement Letter | Executed engagement letter between Calderwood & Harkness LLP and Penterra Pharmaceuticals Corp. regarding legal representation in IRS transfer pricing examination for TY 2017–2020 | Leonard Cross (Calderwood & Harkness LLP) | Marcus Whitfield (Penterra Pharmaceuticals Corp.); Deborah Staines (Penterra Pharmaceuticals Corp.) | Attorney-Client Privilege | Confidential communication between outside counsel and client establishing the scope, terms, and strategy of legal representation in connection with IRS examination defense. |
| PL-002 | 1 | PRIV-000005 – PRIV-000008 | 2022-05-27 | Draft Engagement Letter | Draft engagement letter circulated by Calderwood & Harkness LLP to client for review and comment prior to execution | Leonard Cross (Calderwood & Harkness LLP) | Marcus Whitfield (Penterra Pharmaceuticals Corp.); Deborah Staines (Penterra Pharmaceuticals Corp.) | Attorney-Client Privilege | Confidential communication between outside counsel and client reflecting proposed terms of legal representation and containing legal advice regarding scope of engagement. |
| PL-003 | 4 | PRIV-000009 – PRIV-000015 | 2022-06-15 | Memorandum | Preliminary assessment memorandum regarding IRS examination of PPC transfer pricing positions for TY 2017–2020, including analysis of potential exposure areas, CSA cost-sharing ratios, 4.5% legacy IP royalty rate, and PCT valuation, with recommended defense strategy | Leonard Cross; Garrett Simmons (Calderwood & Harkness LLP) | Marcus Whitfield; Deborah Staines (Penterra Pharmaceuticals Corp.) | Attorney-Client Privilege; Work-Product Doctrine | Confidential memorandum prepared by counsel for the client containing legal analysis, mental impressions, and strategic recommendations regarding the IRS examination. Reflects attorneys' assessment of strengths and weaknesses of PPC's IRC § 482 positions. |
| PL-004 | 4 | PRIV-000016 – PRIV-000032 | 2022-07-12 | Memorandum | Comprehensive defense strategy memorandum outlining three-phase defense plan (IDR response, NOPA/Protest, Appeals), key legal and economic arguments under IRC § 482 and Treas. Reg. §§ 1.482-4, 1.482-7, document preservation protocols, and coordination plan with Whitmore Valuation Group LLC and Thornbury & Keogh | Leonard Cross; Sylvia Hartwell (Calderwood & Harkness LLP) | Marcus Whitfield; Deborah Staines; Rajesh Iyer (Penterra Pharmaceuticals Corp.) | Attorney-Client Privilege; Work-Product Doctrine | Privileged strategic memorandum prepared by counsel containing legal analysis, litigation strategy, and attorneys' mental impressions in anticipation of IRS controversy proceedings. |
| PL-005 | 4 | PRIV-000033 – PRIV-000040 | 2022-06-20 | Kovel Engagement Letter | Executed Kovel engagement letter retaining Whitmore Valuation Group LLC under attorney-client privilege to provide economic analysis in support of Calderwood & Harkness LLP's legal advice to PPC; references C&H Matter Number 1018-00009-KV; identifies Dr. Helena Vasquez as lead economist at blended rate of $650/hr | Leonard Cross (Calderwood & Harkness LLP) | Dr. Helena Vasquez (Whitmore Valuation Group LLC) | Marcus Whitfield (Penterra Pharmaceuticals Corp.) | Attorney-Client Privilege (Kovel Doctrine) | Engagement letter establishing Kovel arrangement under which Whitmore Valuation Group LLC acts as agent of counsel, such that communications with and work product of WVG are protected by attorney-client privilege and work-product doctrine. |
| PL-006 | 5 | PRIV-000041 – PRIV-000078 | 2022-12-01 | Expert Report | PCT valuation analysis prepared by Whitmore Valuation Group LLC under Kovel arrangement — income method / DCF approach revaluing platform contribution transaction using 9.8% WACC; concludes $312M PCT payment within arm's-length range of $278M–$361M; critiques IRS's application of 7.2% discount rate | Dr. Helena Vasquez; Dr. Rohan Chakrabarti (Whitmore Valuation Group LLC) | Leonard Cross; Garrett Simmons (Calderwood & Harkness LLP) | Attorney-Client Privilege (Kovel Doctrine); Work-Product Doctrine | Economic analysis prepared at direction of counsel under Kovel arrangement in anticipation of IRS controversy proceedings. Contains counsel-directed analytical methodology and reflects attorneys' litigation strategy. |
| PL-007 | 5 | PRIV-000079 – PRIV-000098 | 2022-12-01 | Technical Memorandum | Discount rate / WACC analysis supporting use of 9.8% WACC for PCT income-method valuation, including analysis of risk premiums, beta comparables, and pharmaceutical-industry cost of capital; critiques IRS economist Dr. Alan Washburne's application of 7.2% rate | Dr. Helena Vasquez (Whitmore Valuation Group LLC) | Leonard Cross; Garrett Simmons (Calderwood & Harkness LLP) | Attorney-Client Privilege (Kovel Doctrine); Work-Product Doctrine | Technical analysis prepared by Kovel expert at direction of counsel reflecting attorneys' strategic approach to rebutting IRS's PCT valuation methodology. |
| PL-008 | 6 | PRIV-000099 – PRIV-000112 | 2022-07-20 | Legal Research Memorandum | Analysis of IRC § 482 arm's-length standard and best method rule under Treas. Reg. § 1.482-1(d), with discussion of Altera, Harborview Corporation, and Amazon precedents and application to PPC's CSA and royalty methodologies | Leila Nazari; Garrett Simmons (Calderwood & Harkness LLP) | Leonard Cross (Calderwood & Harkness LLP) | Attorney-Client Privilege; Work-Product Doctrine | Legal research memorandum prepared by counsel containing legal analysis, case law evaluation, and attorneys' mental impressions regarding application of the arm's-length standard to PPC's transfer pricing positions. |
| PL-009 | 6 | PRIV-000113 – PRIV-000128 | 2022-08-05 | Legal Research Memorandum | Analysis of qualified cost-sharing arrangement requirements under Treas. Reg. § 1.482-7, PCT payment methodologies, reasonably anticipated benefit shares, and documentary compliance requirements applicable to PPC-PBI CSA | Leila Nazari (Calderwood & Harkness LLP) | Leonard Cross; Garrett Simmons (Calderwood & Harkness LLP) | Attorney-Client Privilege; Work-Product Doctrine | Legal analysis memorandum reflecting counsel's assessment of regulatory compliance and strategic considerations for PPC's QCSA defense. |
| PL-010 | 6 | PRIV-000129 – PRIV-000142 | 2022-08-12 | Legal Research Memorandum | Analysis of arm's-length royalty rate determination under Treas. Reg. § 1.482-4, CUT method requirements, comparability factors for pharmaceutical IP licenses, and legal standards for royalty rate adjustments under IRC § 482 | Garrett Simmons (Calderwood & Harkness LLP) | Leonard Cross (Calderwood & Harkness LLP) | Attorney-Client Privilege; Work-Product Doctrine | Legal analysis reflecting counsel's evaluation of the defensibility of PPC's 4.5% legacy IP royalty rate and strategies for addressing IRS challenge. |
| PL-011 | 8 | PRIV-000143 – PRIV-000158 | 2022-08-18 | Legal Research Memorandum | Analysis of economic substance doctrine in transfer pricing context and DEMPE framework (Development, Enhancement, Maintenance, Protection, Exploitation) under OECD Guidelines, with evaluation of PBI's economic substance in Ireland — 185 employees, 42 board meetings, €47.2M regulatory spend, 18,000 sq ft office, 68 country market pricing decisions | Leila Nazari (Calderwood & Harkness LLP) | Leonard Cross; Garrett Simmons (Calderwood & Harkness LLP) | Attorney-Client Privilege; Work-Product Doctrine | Legal research memorandum reflecting counsel's mental impressions and strategic analysis of PBI's economic substance defense against IRS challenge. |
| PL-012 | 8 | PRIV-000159 – PRIV-000195 | 2022-10-01 | Report / Functional Analysis | Comprehensive functional analysis of Penterra Biopharma International DAC (2017–2020) prepared by C&H in coordination with Whitmore Valuation Group, documenting PBI's functions, assets, and risks including regulatory, commercial-strategy, supply-chain, and medical-affairs activities in Dublin | Garrett Simmons (Calderwood & Harkness LLP); Dr. Helena Vasquez (Whitmore Valuation Group LLC) | Leonard Cross; Sylvia Hartwell (Calderwood & Harkness LLP) | Marcus Whitfield (Penterra Pharmaceuticals Corp.) | Attorney-Client Privilege; Work-Product Doctrine; Kovel Doctrine | Functional analysis prepared at direction of counsel incorporating Kovel expert analysis, reflecting attorneys' strategic approach to demonstrating PBI's substantive role as IP owner and CSA participant. |
| PL-013 | 8 | PRIV-000196 – PRIV-000235 | 2023-03-15 | Report / Updated Functional Analysis | Revised functional analysis of PBI incorporating additional employee interviews (12 key PBI employees) and documentary evidence gathered during 2022–2023 IDR process | Garrett Simmons (Calderwood & Harkness LLP); Dr. Helena Vasquez (Whitmore Valuation Group LLC) | Leonard Cross; Sylvia Hartwell (Calderwood & Harkness LLP) | Marcus Whitfield (Penterra Pharmaceuticals Corp.) | Attorney-Client Privilege; Work-Product Doctrine; Kovel Doctrine | Updated analysis prepared at direction of counsel incorporating additional factual evidence developed during examination, reflecting counsel's evolving litigation strategy. |
| PL-014 | 9 | PRIV-000236 – PRIV-000252 | 2022-09-01 | Memorandum | Analysis of PBI board minutes — catalogue and analysis of 42 board meetings held in Dublin during 2017–2020, documenting key decisions on pricing, market entry, regulatory submissions, and capital expenditures | Leila Nazari (Calderwood & Harkness LLP) | Leonard Cross; Garrett Simmons (Calderwood & Harkness LLP) | Work-Product Doctrine | Analytical memorandum reflecting counsel's selection, organization, and mental impressions regarding PBI governance evidence prepared in anticipation of IRS controversy. |
| PL-015 | 11 | PRIV-000253 – PRIV-000290 | 2022-11-01 | Expert Report | Comparable uncontrolled transaction (CUT) analysis of legacy IP royalty rate — identifies 14 comparable pharmaceutical license agreements with interquartile range of 3.1%–6.8% and median of 4.4%; concludes PPC's 4.5% rate within arm's-length range | Dr. Helena Vasquez; Dr. Rohan Chakrabarti (Whitmore Valuation Group LLC) | Leonard Cross; Garrett Simmons (Calderwood & Harkness LLP) | Attorney-Client Privilege (Kovel Doctrine); Work-Product Doctrine | Economic analysis prepared by Kovel expert at direction of counsel for use in IRS examination defense, reflecting counsel-directed methodology and litigation strategy. |
| PL-016 | 11 | PRIV-000291 – PRIV-000328 | 2022-11-01 | Expert Report | CPM / TNMM analysis testing PBI's operating margins against 22 comparable distributors and IP-holding companies; concludes PBI's margins within interquartile range in all four years (2017–2020) | Dr. Helena Vasquez; Dr. Rohan Chakrabarti (Whitmore Valuation Group LLC) | Leonard Cross; Garrett Simmons (Calderwood & Harkness LLP) | Attorney-Client Privilege (Kovel Doctrine); Work-Product Doctrine | Economic benchmarking analysis prepared by Kovel expert at direction of counsel in anticipation of IRS controversy proceedings. |
| PL-017 | 4 | PRIV-000329 – PRIV-000336 | 2022-09-02 | Legal Research Memorandum | Analysis of IRC § 6662(e) penalty protection and reasonable cause defense, including contemporaneous documentation requirements under IRC § 6662(e)(3)(B) and standards for penalty abatement in transfer pricing cases | Garrett Simmons (Calderwood & Harkness LLP) | Leonard Cross (Calderwood & Harkness LLP) | Attorney-Client Privilege; Work-Product Doctrine | Legal analysis reflecting counsel's assessment of penalty exposure and defense strategies, containing mental impressions regarding the adequacy of PPC's contemporaneous transfer pricing documentation prepared by Crestfield & Associates LLP. |
| PL-018 | 6 | PRIV-000337 – PRIV-000348 | 2022-08-25 | Legal Research Memorandum | Analysis of impact of Tax Cuts and Jobs Act (TCJA, effective January 1, 2018) on PPC's transfer pricing exposure, including rate change from 35% (TY 2017) to 21% (TY 2018–2020) and GILTI/BEAT implications | Leila Nazari (Calderwood & Harkness LLP) | Leonard Cross; Garrett Simmons (Calderwood & Harkness LLP) | Attorney-Client Privilege; Work-Product Doctrine | Legal analysis containing counsel's strategic assessment of how TCJA provisions interact with the IRS's proposed § 482 adjustments. |
| PL-019 | 6 | PRIV-000349 – PRIV-000365 | 2022-09-15 | Legal Research Memorandum | Case law analysis of Altera Corp. v. Commissioner and Harborview Corporation, Inc. v. Commissioner — holdings on stock-based compensation in CSAs and CUT methodology, with applicability assessment to PPC's positions | Garrett Simmons; Leila Nazari (Calderwood & Harkness LLP) | Leonard Cross (Calderwood & Harkness LLP) | Attorney-Client Privilege; Work-Product Doctrine | Legal analysis reflecting counsel's mental impressions regarding the application of controlling precedent to PPC's transfer pricing defense. |
| PL-020 | 6 | PRIV-000366 – PRIV-000378 | 2022-09-28 | Legal Research Memorandum | Analysis of IRC § 367(d) outbound IP transfer considerations — whether IRS might recharacterize the CSA as a § 367(d) transfer and interplay with § 482 | Leila Nazari (Calderwood & Harkness LLP) | Leonard Cross; Garrett Simmons (Calderwood & Harkness LLP) | Attorney-Client Privilege; Work-Product Doctrine | Legal research reflecting counsel's anticipatory analysis of potential IRS recharacterization theories. |
| PL-021 | 6 | PRIV-000379 – PRIV-000392 | 2022-10-10 | Legal Research Memorandum | Analysis of OECD Transfer Pricing Guidelines (2017 & 2022 revisions) as persuasive authority in U.S. tax controversy, focusing on Chapter VI (intangibles) and Chapter VIII (CSAs) | Garrett Simmons (Calderwood & Harkness LLP) | Leonard Cross (Calderwood & Harkness LLP) | Attorney-Client Privilege; Work-Product Doctrine | Legal analysis reflecting counsel's strategic evaluation of OECD guidance as support for PPC's transfer pricing methodology. |
| PL-022 | 4 | PRIV-000393 – PRIV-000402 | 2022-10-01 | Status Report | Q3 2022 matter status report summarizing examination activity, IDR response progress, budget status, and strategic outlook | Leonard Cross; Sylvia Hartwell (Calderwood & Harkness LLP) | Marcus Whitfield; Deborah Staines; Rajesh Iyer (Penterra Pharmaceuticals Corp.) | Attorney-Client Privilege | Confidential privileged communication from outside counsel to client reporting on status of legal representation and containing legal advice and strategic assessments. |
| PL-023 | 6 | PRIV-000403 – PRIV-000412 | 2022-10-01 | Memorandum | Analysis of GILTI and BEAT impact on PPC's transfer pricing positions for TY 2018–2020, including interaction between proposed § 482 adjustments and PPC's GILTI and BEAT computations | Leila Nazari (Calderwood & Harkness LLP) | Leonard Cross; Garrett Simmons (Calderwood & Harkness LLP) | Attorney-Client Privilege; Work-Product Doctrine | Legal analysis reflecting counsel's evaluation of cross-cutting tax reform implications on the examination defense. |
| PL-024 | 1 | PRIV-000413 – PRIV-000418 | 2022-06-10 | Memorandum | Privilege protocol memorandum establishing protocols for maintaining attorney-client privilege and work-product protection during IRS examination, including Kovel arrangement procedures with Whitmore Valuation Group LLC | Leonard Cross (Calderwood & Harkness LLP) | Sylvia Hartwell; Garrett Simmons; Leila Nazari (Calderwood & Harkness LLP) | Attorney-Client Privilege; Work-Product Doctrine | Internal counsel memorandum establishing privileged communication procedures; constitutes work product prepared in anticipation of litigation. |
| PL-025 | 1 | PRIV-000419 – PRIV-000422 | 2022-06-06 | Notice | Document preservation notice / litigation hold directed to PPC, PBI, PHL, and PMI regarding all documents relevant to IRS examination of TY 2017–2020 | Leonard Cross (Calderwood & Harkness LLP) | Deborah Staines (Penterra Pharmaceuticals Corp.); Aidan Naughton (Penterra Biopharma International DAC) | Marcus Whitfield (Penterra Pharmaceuticals Corp.) | Attorney-Client Privilege; Work-Product Doctrine | Communication from counsel directing preservation of documents in anticipation of IRS controversy, reflecting counsel's litigation strategy and identification of relevant issues. |
| PL-026 | 4 | PRIV-000423 – PRIV-000430 | 2022-09-01 | Memorandum | FIN 48 / ASC 740-10 reserve analysis providing legal analysis supporting PPC's $62.4M uncertain tax position reserve related to Irish IP structure, assessing more-likely-than-not and measurement steps | Leonard Cross; Garrett Simmons (Calderwood & Harkness LLP) | Marcus Whitfield (Penterra Pharmaceuticals Corp.); Martin Ogilvy (Crestfield & Associates LLP) | Attorney-Client Privilege; Work-Product Doctrine | Legal analysis from counsel to client and client's auditor containing counsel's assessment of the probability of sustaining PPC's transfer pricing positions — prepared in contemplation of IRS dispute. |
| PL-027 | 4 | PRIV-000431 – PRIV-000434 | 2022-09-20 | Letter | Letter from C&H to Crestfield & Associates LLP (Martin Ogilvy) providing legal analysis in support of PPC's FIN 48 reserve for transfer pricing positions | Leonard Cross (Calderwood & Harkness LLP) | Martin Ogilvy (Crestfield & Associates LLP) | Marcus Whitfield (Penterra Pharmaceuticals Corp.) | Attorney-Client Privilege | Confidential communication from counsel to client's auditor at client's direction, containing legal analysis and opinions regarding PPC's tax positions. |
| PL-028 | 25 | PRIV-000435 – PRIV-000462 | 2022-07-01 | Memorandum | Analysis of CSA agreement effective July 1, 2012 — key terms, compliance with Treas. Reg. § 1.482-7, controlled participant eligibility, intangible development activity, and reasonably anticipated benefits methodology | Garrett Simmons (Calderwood & Harkness LLP) | Leonard Cross (Calderwood & Harkness LLP) | Attorney-Client Privilege; Work-Product Doctrine | Legal analysis of intercompany agreement reflecting counsel's compliance assessment and strategic observations prepared in anticipation of IRS challenge. |
| PL-029 | 3 | PRIV-000463 – PRIV-000478 | 2022-07-01 | Memorandum | Analysis of legacy IP license agreement — royalty rate of 4.5% and terms, compliance with Treas. Reg. § 1.482-4, and arm's-length standard assessment | Leila Nazari (Calderwood & Harkness LLP) | Leonard Cross; Garrett Simmons (Calderwood & Harkness LLP) | Attorney-Client Privilege; Work-Product Doctrine | Legal analysis reflecting counsel's evaluation of the defensibility of the intercompany royalty arrangement. |
| PL-030 | 10 | PRIV-000479 – PRIV-000490 | 2022-08-01 | Memorandum | Analysis of PMI contract manufacturing agreement — cost-plus 8% arrangement between PBI and PMI, arm's-length compliance under cost-plus method | Leila Nazari (Calderwood & Harkness LLP) | Leonard Cross; Garrett Simmons (Calderwood & Harkness LLP) | Attorney-Client Privilege; Work-Product Doctrine | Legal analysis reflecting counsel's assessment of intercompany manufacturing pricing. |
| PL-031 | 1 | PRIV-000491 – PRIV-000498 | 2022-07-01 | Memorandum | Analysis of Penterra Holdings Luxembourg S.à r.l. (PHL) entity classification as disregarded entity for U.S. federal tax purposes and its role as intermediate holding company for PBI (RCS Number B 168452) | Leila Nazari (Calderwood & Harkness LLP) | Leonard Cross; Garrett Simmons (Calderwood & Harkness LLP) | Attorney-Client Privilege; Work-Product Doctrine | Legal analysis of entity structure reflecting counsel's evaluation of classification issues relevant to the examination defense. |
| PL-032 | 8 | PRIV-000499 – PRIV-000530 | 2022-09-15 | Interview Summaries | Summaries of interviews with 12 key PBI employees in Dublin conducted August–September 2022, documenting roles, decision-making authority, and functional contributions to non-Americas commercialization | Garrett Simmons; Leila Nazari (Calderwood & Harkness LLP) | Leonard Cross (Calderwood & Harkness LLP) | Work-Product Doctrine | Interview summaries prepared by counsel reflecting attorneys' selection of witnesses, lines of inquiry, and mental impressions regarding factual support for PBI's economic substance defense. |
| PL-033 | 11 | PRIV-000531 – PRIV-000538 | 2022-08-15 | Email | Email from Cross to Whitfield providing monthly status update on IDR response progress, upcoming deadlines, and coordination with Crestfield & Associates LLP | Leonard Cross (Calderwood & Harkness LLP) | Marcus Whitfield (Penterra Pharmaceuticals Corp.) | Attorney-Client Privilege | Confidential privileged communication from outside counsel to client containing legal advice and strategic assessments regarding examination management. |
| PL-034 | 11 | PRIV-000539 – PRIV-000544 | 2022-10-05 | Email | Internal email from Cross to Hartwell discussing IRS exam team's apparent focus on royalty rate and PBI substance, with strategic observations | Leonard Cross (Calderwood & Harkness LLP) | Sylvia Hartwell (Calderwood & Harkness LLP) | Attorney-Client Privilege; Work-Product Doctrine | Internal attorney communication reflecting counsel's mental impressions and strategic analysis of IRS examination focus areas. |
| PL-035 | 25 | PRIV-000545 – PRIV-000550 | 2022-06-21 | Email | Email from Cross to Dr. Vasquez (Whitmore Valuation Group) outlining scope of economic analysis work and initial data requirements following execution of Kovel letter | Leonard Cross (Calderwood & Harkness LLP) | Dr. Helena Vasquez (Whitmore Valuation Group LLC) | Attorney-Client Privilege (Kovel Doctrine); Work-Product Doctrine | Direction from counsel to Kovel expert reflecting counsel's litigation strategy and analytical framework for transfer pricing economic analysis. |
| PL-036 | 30 | PRIV-000551 – PRIV-000558 | 2022-08-12 | Email | Email from Nazari to Ciarán Thornbury (Thornbury & Keogh) coordinating on Irish tax aspects, requesting PBI's Irish Revenue filings and Knowledge Development box documentation (6.25% effective rate) | Leila Nazari (Calderwood & Harkness LLP) | Ciarán Thornbury (Thornbury & Keogh) | Leonard Cross (Calderwood & Harkness LLP) | Attorney-Client Privilege; Work-Product Doctrine | Communication between counsel and client's Irish tax advisors at direction of counsel in connection with coordinated multi-jurisdiction examination defense strategy. |
| PL-037 | 22 | PRIV-000559 – PRIV-000564 | 2022-11-15 | Email | Email from Nazari to Thornbury requesting additional PBI substance documentation including lease agreements, employee contracts, and Glenmore Bank Ireland plc account records | Leila Nazari (Calderwood & Harkness LLP) | Ciarán Thornbury (Thornbury & Keogh) | Leonard Cross (Calderwood & Harkness LLP) | Attorney-Client Privilege; Work-Product Doctrine | Communication between counsel and client's Irish advisors reflecting counsel's strategic identification of evidence needed for economic substance defense. |
| PL-038 | 35 | PRIV-000565 – PRIV-000572 | 2023-03-15 | Email / Status Report | Status update from Cross to Whitfield covering mid-examination developments, IRS economist Dr. Alan Washburne's involvement, and anticipated NOPA timeline | Leonard Cross (Calderwood & Harkness LLP) | Marcus Whitfield (Penterra Pharmaceuticals Corp.) | Attorney-Client Privilege | Confidential privileged communication from counsel to client containing legal advice, strategic assessments, and counsel's evaluation of IRS examination trajectory. |
| PL-039 | 35 | PRIV-000573 – PRIV-000580 | 2023-07-20 | Email / Status Report | Status update discussing intelligence on IRS economist's analysis direction, potential adjustment amounts, and strategic positioning | Leonard Cross (Calderwood & Harkness LLP) | Marcus Whitfield (Penterra Pharmaceuticals Corp.) | Attorney-Client Privilege; Work-Product Doctrine | Privileged communication containing counsel's mental impressions regarding anticipated IRS positions and strategic countermeasures. |
| PL-040 | 40 | PRIV-000581 – PRIV-000588 | 2023-01-05 | Status Report | Q4 2022 quarterly matter status report | Leonard Cross; Sylvia Hartwell (Calderwood & Harkness LLP) | Marcus Whitfield; Deborah Staines (Penterra Pharmaceuticals Corp.) | Attorney-Client Privilege | Confidential privileged status report from counsel to client. |
| PL-041 | 40 | PRIV-000589 – PRIV-000596 | 2023-04-03 | Status Report | Q1 2023 quarterly matter status report | Leonard Cross; Sylvia Hartwell (Calderwood & Harkness LLP) | Marcus Whitfield; Deborah Staines (Penterra Pharmaceuticals Corp.) | Attorney-Client Privilege | Confidential privileged status report from counsel to client. |
| PL-042 | 40 | PRIV-000597 – PRIV-000604 | 2023-07-05 | Status Report | Q2 2023 quarterly matter status report | Leonard Cross; Sylvia Hartwell (Calderwood & Harkness LLP) | Marcus Whitfield; Deborah Staines (Penterra Pharmaceuticals Corp.) | Attorney-Client Privilege | Confidential privileged status report from counsel to client. |
| PL-043 | 44 | PRIV-000605 – PRIV-000612 | 2023-10-03 | Status Report | Q3 2023 quarterly matter status report covering the NOPA issuance on October 12, 2023 | Leonard Cross; Sylvia Hartwell (Calderwood & Harkness LLP) | Marcus Whitfield; Deborah Staines (Penterra Pharmaceuticals Corp.) | Attorney-Client Privilege | Confidential privileged status report from counsel to client. |
| PL-044 | 47 | PRIV-000613 – PRIV-000650 | 2023-10-20 | Memorandum | Detailed analysis of Notice of Proposed Adjustment (NOPA) issued October 12, 2023 — breaks down $380.4M proposed adjustments (CSA: $235.01M, royalty: $188.04M, correlative offset: -$42.65M), assesses IRS legal and economic positions, identifies vulnerabilities | Garrett Simmons; Leila Nazari (Calderwood & Harkness LLP) | Leonard Cross; Sylvia Hartwell (Calderwood & Harkness LLP) | Attorney-Client Privilege; Work-Product Doctrine | Analytical memorandum reflecting counsel's mental impressions, legal analysis, and strategic assessment of the IRS's proposed adjustments, prepared in anticipation of Appeals proceedings. |
| PL-045 | 47 | PRIV-000651 – PRIV-000660 | 2023-11-01 | Memorandum | Analysis of 30-Day Letter issued November 8, 2023 — procedural options (Protest to Appeals vs. Tax Court petition), deadlines, and strategic considerations | Leila Nazari (Calderwood & Harkness LLP) | Leonard Cross (Calderwood & Harkness LLP) | Attorney-Client Privilege; Work-Product Doctrine | Legal analysis reflecting counsel's assessment of procedural alternatives and recommended course of action. |
| PL-046 | 47 | PRIV-000661 – PRIV-000668 | 2023-10-15 | Email | Email from Cross to Whitfield reporting receipt and initial assessment of the NOPA, summarizing $380.4M proposed adjustments (CSA $235.01M + royalty $188.04M – offset $42.65M), recommending immediate conference call | Leonard Cross (Calderwood & Harkness LLP) | Marcus Whitfield (Penterra Pharmaceuticals Corp.) | Attorney-Client Privilege | Confidential privileged communication from counsel to client containing legal analysis and strategic recommendations. |
| PL-047 | 47 | PRIV-000669 – PRIV-000676 | 2023-11-09 | Email | Email from Cross to Whitfield discussing 30-Day Letter received November 8, 2023, explaining options and recommending Protest filing with extension request | Leonard Cross (Calderwood & Harkness LLP) | Marcus Whitfield (Penterra Pharmaceuticals Corp.) | Attorney-Client Privilege | Confidential privileged communication containing counsel's legal advice on procedural strategy. |
| PL-048 | 47 | PRIV-000677 – PRIV-000690 | 2023-10-23 | Memorandum | Analysis of correlative adjustments under Treas. Reg. § 1.482-1(g) — availability and mechanics to avoid double-counting between CSA and royalty adjustments, supporting $42.65M offset | Leila Nazari (Calderwood & Harkness LLP) | Leonard Cross; Garrett Simmons (Calderwood & Harkness LLP) | Attorney-Client Privilege; Work-Product Doctrine | Legal research memorandum reflecting counsel's analysis of regulatory basis for correlative adjustment supporting reduction of proposed total adjustment. |
| PL-049 | 47 | PRIV-000691 – PRIV-000704 | 2023-11-01 | Memorandum | Analysis of Hargrove National Bank credit facility ($1.5B revolving facility) tax-indemnity and material-tax-event covenants — whether $380.4M proposed adjustment triggers reporting or default provisions | Leila Nazari (Calderwood & Harkness LLP) | Leonard Cross (Calderwood & Harkness LLP); Deborah Staines (Penterra Pharmaceuticals Corp.) | Attorney-Client Privilege; Work-Product Doctrine | Legal analysis reflecting counsel's assessment of contractual implications of the IRS examination, containing legal advice and strategic recommendations. |
| PL-050 | 47 | PRIV-000705 – PRIV-000718 | 2023-11-01 | Memorandum | Analysis of SEC disclosure obligations (10-K, 10-Q) regarding IRS examination, contingent liabilities, and FIN 48 reserves, considering Ridgeview Capital Management LP's (8.3% shareholder) monitoring | Garrett Simmons (Calderwood & Harkness LLP) | Leonard Cross (Calderwood & Harkness LLP); Deborah Staines (Penterra Pharmaceuticals Corp.) | Attorney-Client Privilege; Work-Product Doctrine | Legal analysis reflecting counsel's evaluation of public disclosure considerations in light of IRS examination. |
| PL-051 | 47 | PRIV-000719 – PRIV-000730 | 2023-11-20 | Letter | Updated letter to Crestfield & Associates LLP (Martin Ogilvy) providing revised legal conclusions following NOPA for use in PPC's year-end 2023 FIN 48 reserve analysis — $62.4M reserve reassessment | Leonard Cross (Calderwood & Harkness LLP) | Martin Ogilvy (Crestfield & Associates LLP) | Marcus Whitfield (Penterra Pharmaceuticals Corp.) | Attorney-Client Privilege | Confidential communication from counsel to client's auditor at client's direction, containing updated legal opinions regarding PPC's uncertain tax position reserve. |
| PL-052 | 47 | PRIV-000731 – PRIV-000745 | 2023-11-01 | Updated FIN 48 Analysis | Updated FIN 48 / ASC 740-10 analysis reassessing $62.4M reserve in light of $380.4M proposed adjustments and counsel's assessment of litigation hazards | Leonard Cross; Garrett Simmons (Calderwood & Harkness LLP) | Marcus Whitfield (Penterra Pharmaceuticals Corp.) | Attorney-Client Privilege; Work-Product Doctrine | Legal analysis containing counsel's probability-weighted assessment of PPC's tax positions, prepared for the purpose of rendering legal advice regarding financial statement reserves. |
| PL-053 | 47 | PRIV-000746 – PRIV-000752 | 2023-11-25 | Email | Email from Cross to General Counsel Staines regarding SEC disclosure considerations for PPC's upcoming 10-K filing in light of $380.4M proposed adjustment | Leonard Cross (Calderwood & Harkness LLP) | Deborah Staines (Penterra Pharmaceuticals Corp.) | Marcus Whitfield (Penterra Pharmaceuticals Corp.) | Attorney-Client Privilege | Confidential privileged communication from counsel to client's general counsel containing legal advice on securities disclosure obligations. |
| PL-054 | 47 | PRIV-000753 – PRIV-000780 | 2023-12-01 | Memorandum | Appeals strategy memorandum outlining strategy for IRS Appeals, including settlement posture, hazards-of-litigation analysis, recommended opening and target positions, and conference preparation | Leonard Cross; Sylvia Hartwell (Calderwood & Harkness LLP) | Marcus Whitfield; Deborah Staines (Penterra Pharmaceuticals Corp.) | Attorney-Client Privilege; Work-Product Doctrine | Privileged strategic memorandum containing counsel's mental impressions, litigation risk assessment, and recommended settlement parameters. |
| PL-055 | 47 | PRIV-000781 – PRIV-000798 | 2023-12-05 | Memorandum | Hazards of litigation analysis — probability-weighted assessment of potential Tax Court outcomes on each IRS position (CSA cost-sharing, royalty rate, economic substance), with assigned risk ranges | Leonard Cross (Calderwood & Harkness LLP) | Sylvia Hartwell (Calderwood & Harkness LLP) | Attorney-Client Privilege; Work-Product Doctrine | Highly privileged work-product memorandum containing counsel's core mental impressions and litigation risk assessments. |
| PL-056 | 47 | PRIV-000799 – PRIV-000808 | 2023-12-10 | Memorandum | Settlement authority memorandum recommending settlement authority parameters for Appeals: target resolution at 10–15% of proposed $380.4M adjustment, with hard ceiling of 20% | Leonard Cross (Calderwood & Harkness LLP) | Marcus Whitfield; Deborah Staines (Penterra Pharmaceuticals Corp.) | Attorney-Client Privilege; Work-Product Doctrine | Privileged settlement recommendation reflecting counsel's litigation risk assessment, mental impressions, and strategic advice regarding case resolution. |
| PL-057 | 47 | PRIV-000809 – PRIV-000818 | 2023-12-01 | Memorandum | Analysis of potential competent authority relief under U.S.-Ireland Income Tax Treaty to avoid double taxation in event of § 482 adjustment, and whether to pursue a MAP request | Leonard Cross (Calderwood & Harkness LLP) | Marcus Whitfield; Deborah Staines (Penterra Pharmaceuticals Corp.) | Attorney-Client Privilege; Work-Product Doctrine | Legal analysis reflecting counsel's evaluation of treaty-based relief mechanisms and strategic recommendations. |
| PL-058 | 47 | PRIV-000819 – PRIV-000860 | 2024-01-01 | Expert Report / Rebuttal | Rebuttal of IRS economist Dr. Alan Washburne's analysis — challenges CUT selection criteria, discount rate assumptions (7.2% vs. 9.8% WACC), and projected revenue growth rates underlying NOPA | Dr. Helena Vasquez; Dr. Rohan Chakrabarti (Whitmore Valuation Group LLC) | Leonard Cross; Garrett Simmons (Calderwood & Harkness LLP) | Attorney-Client Privilege (Kovel Doctrine); Work-Product Doctrine | Rebuttal analysis prepared by Kovel expert at counsel's direction in anticipation of Appeals proceedings, reflecting counsel's litigation strategy. |
| PL-059 | 47 | PRIV-000861 – PRIV-000870 | 2024-01-05 | Email | Email from Cross to Dr. Vasquez requesting preparation of rebuttal memorandum addressing Dr. Washburne's economic analysis for use in Appeals | Leonard Cross (Calderwood & Harkness LLP) | Dr. Helena Vasquez (Whitmore Valuation Group LLC) | Attorney-Client Privilege (Kovel Doctrine); Work-Product Doctrine | Direction from counsel to Kovel expert reflecting counsel's strategic priorities for Appeals proceedings. |
| PL-060 | 47 | PRIV-000871 – PRIV-000880 | 2024-01-05 | Email | Email from Nazari to Ciarán Thornbury (Thornbury & Keogh) discussing potential mutual agreement procedure request under U.S.-Ireland treaty and Irish Revenue coordination | Leila Nazari (Calderwood & Harkness LLP) | Ciarán Thornbury (Thornbury & Keogh) | Leonard Cross (Calderwood & Harkness LLP) | Attorney-Client Privilege; Work-Product Doctrine | Communication between counsel and client's Irish advisors at direction of counsel regarding coordinated multi-jurisdiction strategy. |
| PL-061 | 47 | PRIV-000881 – PRIV-000900 | 2024-02-15 | Memorandum | Appeals pre-conference memorandum summarizing key arguments, anticipated Appeals Officer Castañeda questions, witness preparation notes, and conference logistics for February 28, 2024 at IRS Appeals Office, Manhattan | Leonard Cross (Calderwood & Harkness LLP) | Sylvia Hartwell; Garrett Simmons (Calderwood & Harkness LLP); Marcus Whitfield; Deborah Staines (Penterra Pharmaceuticals Corp.) | Attorney-Client Privilege; Work-Product Doctrine | Privileged conference preparation memorandum reflecting counsel's mental impressions, strategy, and anticipation of IRS Appeals proceedings. |
| PL-062 | 47 | PRIV-000901 – PRIV-000910 | 2024-02-20 | Witness Preparation Memorandum | Preparation memorandum for Marcus Whitfield for potential testimony/statements at Appeals conference — key facts, anticipated questions, and messaging | Leonard Cross (Calderwood & Harkness LLP) | Marcus Whitfield (Penterra Pharmaceuticals Corp.) | Attorney-Client Privilege; Work-Product Doctrine | Privileged witness preparation document reflecting counsel's mental impressions, anticipated issues, and strategic advice for client witness. |
| PL-063 | 47 | PRIV-000911 – PRIV-000920 | 2024-02-22 | Witness Preparation Memorandum | Preparation memorandum for Dr. Helena Vasquez to present Whitmore's economic analyses at Appeals conference | Garrett Simmons (Calderwood & Harkness LLP) | Dr. Helena Vasquez (Whitmore Valuation Group LLC) | Leonard Cross (Calderwood & Harkness LLP) | Attorney-Client Privilege (Kovel Doctrine); Work-Product Doctrine | Privileged witness preparation document for Kovel expert reflecting counsel's strategic direction for expert presentation at Appeals. |
| PL-064 | 47 | PRIV-000921 – PRIV-000928 | 2024-02-15 | Email | Internal email outlining preparation tasks for February 28 Appeals conference including presentation finalization, document binders, and role assignments | Leonard Cross (Calderwood & Harkness LLP) | Sylvia Hartwell; Garrett Simmons; Leila Nazari (Calderwood & Harkness LLP) | Attorney-Client Privilege; Work-Product Doctrine | Internal attorney communication reflecting counsel's litigation preparation strategy. |
| PL-065 | 47 | PRIV-000929 – PRIV-000948 | 2024-03-01 | Memorandum | Post-conference summary of IRS Appeals conference held February 28, 2024 — Appeals Officer Castañeda's questions and reactions, areas of agreement and disagreement, next steps | Garrett Simmons (Calderwood & Harkness LLP) | Leonard Cross; Sylvia Hartwell (Calderwood & Harkness LLP) | Attorney-Client Privilege; Work-Product Doctrine | Internal counsel memorandum reflecting attorneys' mental impressions and strategic observations from Appeals proceedings. |
| PL-066 | 47 | PRIV-000949 – PRIV-000956 | 2024-03-01 | Email | Email from Cross to Whitfield, Staines, and Iyer debriefing the Appeals conference — Castañeda's receptiveness and likely settlement trajectory | Leonard Cross (Calderwood & Harkness LLP) | Marcus Whitfield; Deborah Staines; Rajesh Iyer (Penterra Pharmaceuticals Corp.) | Attorney-Client Privilege | Confidential privileged communication from counsel to client containing legal advice and strategic assessment of Appeals outcome. |
| PL-067 | 47 | PRIV-000957 – PRIV-000980 | 2024-03-18 | Memorandum | Analysis of Appeals settlement offer of $47.6M (12.51% of $380.4M) — allocation by year ($11.2M / $12.4M / $12.8M / $11.2M), full penalty abatement, tax due ($10.0M at 21%), estimated interest ($2.84M), and recommendation to accept | Leonard Cross; Sylvia Hartwell (Calderwood & Harkness LLP) | Marcus Whitfield; Deborah Staines; Rajesh Iyer (Penterra Pharmaceuticals Corp.) | Attorney-Client Privilege; Work-Product Doctrine | Privileged settlement analysis containing counsel's recommendation, risk assessment, and financial impact calculations. |
| PL-068 | 47 | PRIV-000981 – PRIV-000988 | 2024-03-18 | Email | Email from Cross to Whitfield and Staines transmitting settlement offer analysis memo and recommending acceptance of $47.6M settlement | Leonard Cross (Calderwood & Harkness LLP) | Marcus Whitfield; Deborah Staines (Penterra Pharmaceuticals Corp.) | Attorney-Client Privilege | Confidential privileged communication containing counsel's settlement recommendation. |
| PL-069 | 47 | PRIV-000989 – PRIV-000994 | 2024-03-21 | Email | Email from Whitfield to Cross confirming PPC management (Iyer, Falk) has approved acceptance of $47.6M settlement | Marcus Whitfield (Penterra Pharmaceuticals Corp.) | Leonard Cross (Calderwood & Harkness LLP) | Deborah Staines (Penterra Pharmaceuticals Corp.) | Attorney-Client Privilege | Confidential privileged communication from client to counsel conveying settlement authorization. |
| PL-070 | 47 | PRIV-000995 – PRIV-001010 | 2024-03-01 | FIN 48 Analysis | Final FIN 48 / ASC 740-10 analysis post-settlement — documents reduction of reserve from $62.4M to $14.8M and basis for remaining reserve | Leonard Cross; Garrett Simmons (Calderwood & Harkness LLP) | Marcus Whitfield (Penterra Pharmaceuticals Corp.); Martin Ogilvy (Crestfield & Associates LLP) | Attorney-Client Privilege; Work-Product Doctrine | Legal analysis containing counsel's assessment of remaining uncertain tax positions following settlement, prepared for client and client's auditor. |
| PL-071 | 47 | PRIV-001011 – PRIV-001018 | 2024-03-19 | Email | Email from Cross to CFO Rajesh Iyer summarizing total financial impact of settlement: tax $10.0M, interest ~$2.84M, $0 penalty, total cash cost ~$12.84M, plus impact on FIN 48 reserve | Leonard Cross (Calderwood & Harkness LLP) | Rajesh Iyer (Penterra Pharmaceuticals Corp.) | Marcus Whitfield; Deborah Staines (Penterra Pharmaceuticals Corp.) | Attorney-Client Privilege | Confidential privileged communication from counsel to client containing legal and financial analysis of settlement impact. |
| PL-072 | 47 | PRIV-001019 – PRIV-001026 | 2024-03-20 | Email | Email from Nazari to Thornbury (Thornbury & Keogh) analyzing potential Irish tax consequences of $47.6M U.S. settlement, including impact on PBI's Knowledge Development box claims | Leila Nazari (Calderwood & Harkness LLP) | Ciarán Thornbury (Thornbury & Keogh) | Leonard Cross (Calderwood & Harkness LLP) | Attorney-Client Privilege; Work-Product Doctrine | Communication between counsel and client's Irish advisors reflecting counsel's analysis of cross-border tax implications of settlement. |
| Field | Value |
| Matter Name | IRS Transfer Pricing Examination Defense — Penterra Pharmaceuticals Corp. |
| Calderwood & Harkness LLP Matter Number | 1018-00009 |
| Client | Penterra Pharmaceuticals Corp. (EIN 22-3741856) |
| Client Address | 2200 Independence Boulevard, Princeton Junction, NJ 08550 |
| Nasdaq Ticker | PPCA |
| Tax Years Under Examination | 2017, 2018, 2019, 2020 |
| IRS Exam Team ID | LB&I-NE-TP-2022-00641 |
| IRS Supervisory Revenue Agent | Gerald Meskill |
| IRS Lead Revenue Agent | Patricia Dunleavy |
| Examination Opened | May 16, 2022 |
| IDR Period | June 2022 – September 2023 (47 IDRs issued) |
| Total IDRs Issued | 47 |
| Privilege Log Prepared By | Garrett Simmons; Leila Nazari — Calderwood & Harkness LLP |
| Privilege Log Reviewed By | Leonard Cross — Responsible Partner, Calderwood & Harkness LLP |
| C&H Office Address (Lead) | 1735 Market Street, Suite 3100, Philadelphia, PA 19103 |
| C&H Headquarters | 600 Lexington Avenue, New York, NY 10022 |
| Power of Attorney Filed | IRS Form 2848, June 8, 2022 (covers Leonard Cross, Sylvia Hartwell, Garrett Simmons, Leila Nazari) |
| Entities Covered | Penterra Pharmaceuticals Corp.; Penterra Biopharma International DAC; Penterra Holdings Luxembourg S.à r.l.; Penterra Manufacturing Ireland Ltd. |
| Kovel Expert | Whitmore Valuation Group LLC (Kovel Letter Ref: 1018-00009-KV, executed June 20, 2022) |
| Total Entries on Privilege Log | 72 |
| Bates Range | PRIV-000001 through PRIV-001026 |
| Date of Log | October 15, 2023 (initial); updated through March 29, 2024 |
| Certification | This privilege log is submitted pursuant to the assertion of attorney-client privilege and/or work-product doctrine. Penterra Pharmaceuticals Corp. does not waive any privilege or protection by providing this log. |